髓外急性髓系白血病的表达谱分析提示上皮-间质转化通路参与
本研究应用RNA测序技术分析13例急性髓系白血病(AML)的转录组,其中9例有髓外(EM)定位,发现EM部位细胞外基质-受体相互作用和黏着斑通路显著失调,TWIST1在EM-AML中显著上调。在OCI-AML3细胞中,TWIST1-siRNA或二甲双胍处理48小时后TWIST1及EMT相关基因FN1和SNAI2下调,并显著损害迁移和侵袭能力。
要点
- 髓外AML中细胞外基质-受体相互作用和黏着斑通路显著失调。
- TWIST1在髓外AML中显著上调,可能成为EM-AML进展的候选标志物。
- 二甲双胍可下调TWIST1及EMT相关基因FN1和SNAI2,并损害迁移和侵袭。
核心结论
- 髓外AML组织中细胞外基质-受体相互作用和黏着斑通路显著失调,TWIST1显著上调,抑制EMT通路可能为预防或治疗该并发症提供创新治疗干预。
研究设计与样本
- 应用RNA测序技术分析13例AML的转录组,其中9例有髓外定位。
- 在OCI-AML3细胞中分别用TWIST1-siRNA或二甲双胍处理48小时,用Boyden小室实验检测迁移和侵袭。
主要发现
- 髓外部位细胞外基质-受体相互作用和黏着斑通路显著失调。
- TWIST1在髓外AML中显著上调。
- OCI-AML3细胞经TWIST1-siRNA或二甲双胍处理48小时后,TWIST1及EMT相关基因FN1和SNAI2下调,迁移和侵袭过程显著受损。
关键数值与推荐
- 髓外定位在AML患者中发生率约10%。
- 转录组分析纳入13例AML,其中9例有髓外定位。
- 功能实验中处理时间为48小时。
临床怎么用
- 原文未据此给出推荐。
- 作者认为TWIST1可能成为EM-AML进展的候选标志物。
- 作者认为抑制EMT通路可能代表一种预防或治疗该并发症的创新治疗干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extramedullary (EM) colonization is a rare complication of acute myeloid leukemia (AML), occurring in about 10% of patients, but the processes underlying tissue invasion are not entirely characterized. Through the application of RNAseq technology, we examined the transcriptome profile of 13 AMLs, 9 of whom presented an EM localization. Our analysis revealed significant deregulation within the extracellular matrix (ECM)-receptor interaction and focal-adhesion pathways, specifically in the EM sites. The transcription factor TWIST1, which is known to impact on cancer invasion by dysregulating epithelial-mesenchymal-transition (EMT) processes, was significantly upregulated in EM-AML. To test the functional impact of TWIST1 overexpression, we treated OCI-AML3s with TWIST1-siRNA or metformin, a drug known to inhibit tumor progression in cancer models. After 48 h, we showed downregulation of TWIST1, and of the EMT-related genes FN1 and SNAI2. This was associated with significant impairment of migration and invasion processes by Boyden chamber assays. Our study shed light on the molecular mechanisms associated with EM tissue invasion in AML, and on the ability of metformin to interfere with key players of this process. TWIST1 may configure as candidate marker of EM-AML progression, and inhibition of EMT-pathways may represent an innovative therapeutic intervention to prevent or treat this complication.
引用
- Ottone T, Silvestrini G, Piazza R, et al. Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways. Leukemia. 2023. PMID: 37803061. doi:10.1038/s41375-023-02054-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。